Participated · Seed · Jul 2026

Walden Robotics develops and deploys general-purpose robots powered by Large Behavior Models and other Physical AI advances to perform useful work in manufacturing, logistics, and other industries. Founded in 2026 and launched out of Toyota Research Institute, the company combines foundational robotics research with in-house operations teams to bring robots into production environments. Walden reports that its robots have been operating in production at a Toyota plant in North America since February, progressing from pilot to real work in under two months. The company has strategic partnerships across automotive, aerospace, semiconductors, electronics, logistics, and life sciences and emphasizes human-centered deployment where robots work side-by-side with people. Walden’s stated plans center on scaling commercial deployments and continuous on-the-job learning to improve capabilities over time. Financially, the company announced a $300 million seed round at a $1.1 billion valuation led by Toyota and Deviation Capital, providing capital to support its launch and customer expansion.

Participated · Series C · May 2026

Daloopa provides structured, source-linked financial data covering over 5,500 public companies globally and delivers up to ten times more data points per company than other providers. Each datapoint is linked to its original source to enable auditability for high‑stakes finance use cases like valuation, earnings analysis, and portfolio modeling. The platform is integrated with MCP connectors for OpenAI ChatGPT, Anthropic Claude, Perplexity, and Rogo and offers programmatic access via API plus cloud-native delivery through Snowflake, Databricks, and AWS S3. Daloopa also introduced a Partner API to let third-party products and startups leverage its data. The company says it is trusted by over 160 financial institutions and has doubled revenue over the past year. Its stated focus is expanding platform capabilities and team headcount to support AI-driven, production-grade financial workflows.

Participated · Series B · Oct 2025

CurbWaste offers an operating system purpose-built for independent waste haulers, replacing the paper and legacy tools that many family-run operators still rely on. The cloud platform streamlines dispatch, compliance, and customer service, delivering time savings, lower costs, and a stronger competitive position for its users. Today the company supports 150 haulers nationwide, ranging from small family businesses to large regional fleets. Customers report dramatic quality-of-life improvements—for example, owners can now dispatch remotely instead of arriving at 3 a.m. to manage paperwork. With total funding now at $50 million, CurbWaste plans to expand its team, invest in go-to-market efforts, and build new artificial-intelligence and machine-learning features tailored to waste-industry complexities. The company believes these AI tools will help haulers grow revenue, eliminate cost centers, and enhance customer service. It is positioning itself within a U.S. waste-management software market valued at $4.3 billion in 2023 and projected to nearly double by 2030.

Participated · Equity · Feb 2024

Freenome develops blood-based screening tests for early cancer detection using a multiomics platform that combines computational biology, machine learning, and other technologies. Its initial programs focus on colorectal and lung cancers, with single-cancer and tailored multi-cancer tests under development. The platform is also being evaluated with biopharma and diagnostic partners to non-invasively detect minimal residual disease (MRD) augmented by biological insights. The company has registrational studies underway, including PREEMPT CRC (>40,000 participants) and PROACT LUNG (up to 20,000 participants), plus multi-cancer research programs such as the Vallania Study (more than 6,200 participants) and additional studies totaling >10,000 paired RWD participants. Freenome intends to use the newly raised funds to advance its pipeline of single-cancer and multi-cancer early detection tests. The company is led by CEO Mike Nolan and is based in San Francisco, CA. Freenome develops a multiomics platform that uses routine blood draws to detect cancer in its earliest stages. Its core product is a blood test for colorectal cancer (CRC) being validated in the large prospective registrational study PREEMPT CRC, which is nearing completion of enrollment. The company plans to commercialize the CRC screening test and expand the platform to detect other cancers, and has reported promising data in pancreatic cancer detection. Freenome combines molecular biology, computational biology, and machine learning to identify disease-associated patterns among circulating cell-free biomarkers. Financially, Freenome announced a $300M Series D and has raised over $800M in total financing since its 2014 founding. The new funding is intended to support commercialization and further development of multi-cancer tests. Freenome has developed a comprehensive multiomics platform to detect cancer early from a routine blood draw, beginning with a colorectal cancer screening test. The platform integrates genomics, transcriptomics, methylomics, and proteomics with advanced computational biology and machine learning to recognize disease-associated patterns among circulating cell-free biomarkers. Freenome launched the PREEMPT CRC FDA registrational clinical trial in May 2020 to support approval of its first front-line blood test for colorectal cancer screening and precancerous lesion detection. The company intends to use proceeds from the financing to accelerate PREEMPT CRC toward approval, reimbursement, and commercialization, advance a pipeline of blood tests for additional cancers, and continue building its proprietary multiomics platform. Financially, Freenome closed an oversubscribed $270 million Series C that brings total financing to over $500 million since the company’s launch. The company is headquartered in South San Francisco, California. Freenome has built a multiomics platform that integrates assays for cell-free DNA, methylation, and proteins with computational biology and machine learning to detect early signs of cancer from a routine blood draw. The company’s first test targets colorectal cancer and uses a multidimensional view of tumor- and immune-derived signatures to improve sensitivity and specificity. Freenome reported promising clinical results at Digestive Disease Week showing high sensitivity and specificity in a cohort of mostly early-stage colorectal cancer patients. The company plans a pivotal validation study and intends to submit to the FDA and CMS under the Parallel Review Program for its colorectal cancer screening application. Proceeds from its recent financing will also fund expansion of laboratory infrastructure and software to support growth and future development. Freenome is headquartered in South San Francisco and was founded in 2014. Freenome is a health-technology company combining machine learning, biology and computer science to develop non-invasive disease screening assays based on cell-free DNA and other analytes. The company has collaborated with more than 25 research partners, including UCSD Moores Cancer Center, UCSF and MGH, and has processed thousands of samples through research and clinical trials. Freenome is working with five pharmaceutical companies to validate its software for clinical trial stratification and precision prescribing. The company is focused on scaling its technology and improving screening accuracy for lung, colorectal, breast and prostate cancers, with plans to address additional cancers and diseases. Proceeds from the Series A financing are being used to accelerate clinical trials, expand research, and advance its first products toward regulatory review. Headquartered in South San Francisco and launched in 2014, Freenome has raised more than $70 million since founding.

Participated · Equity · Nov 2023

RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a therapy that uses a single radiotracer injection to generate real-time signals to guide autonomous radiotherapy. SCINTIX is delivered via the RefleXion X1, a dual-treatment modality platform that also provides image-guided radiotherapy. The company positions SCINTIX to treat all stages of indicated solid tumor cancers, including metastatic disease, by addressing targeting and motion-management barriers. SCINTIX has received FDA De Novo marketing authorization and a Breakthrough Device designation for lung tumors, and is indicated for FDG-guided treatment of lung and bone tumors. The X1 platform is also cleared for image-guided external-beam radiotherapy for solid tumors located anywhere in the body. RefleXion plans to use proceeds from its recent equity raise to extend commercialization of SCINTIX therapy. RefleXion Medical is a privately held therapeutic oncology company developing biology-guided radiotherapy (BgRT) and commercializing the RefleXion X1 radiotherapy platform. The X1 is cleared for delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is developing BgRT, which uses PET imaging to enable tumors to continuously signal their location and synchronize that data with a linear accelerator. RefleXion is pursuing commercialization of X1 while preparing BgRT for regulatory review and future clinical use. The company is building a radiopharmaceutical program and has a co-development agreement with Telix Pharmaceuticals to explore a PSMA-targeted PET tracer for use with BgRT. RefleXion recently hosted a cancer symposium with clinicians from 30 top U.S. cancer programs to support clinical engagement and adoption. RefleXion Medical is a privately-held therapeutic oncology company developing biology-guided radiotherapy (BgRT) and the RefleXion X1 system to enable treatment of multiple tumors, including metastatic disease. The X1 is currently cleared for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT), while BgRT is pending regulatory review and not commercially available. BgRT incorporates PET radiotracer imaging to continuously signal tumor location and synchronizes those data with a linear accelerator to direct radiotherapy with subsecond latency. The company has positioned BgRT to expand radiotherapy to late-stage cancers and the technology recently received FDA Breakthrough Device designation for use in lung tumors. RefleXion reports delivering nearly 2,000 patient treatments, completing a feasibility study, securing an additional radiopharmaceutical agreement, and expanding its commercial footprint. The $80 million financing will fund further development and commercialization of the BgRT platform. RefleXion develops the RefleXion X1 system and is pioneering biology-guided radiotherapy (BgRT), which uses PET imaging data to enable tumors to continuously signal their location and allow radiotherapy with sub-second latency. The X1 is currently cleared for delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT); the BgRT capability requires additional 510(k) clearance and is not yet available for sale. The company says BgRT is designed to scale radiotherapy from one or two tumors to all visible tumors, including those that move rapidly due to breathing or digestion, in the same treatment session. Commercialization efforts began in mid-2020 and the company reports a promising market ramp since then. Financially, RefleXion completed a Series D financing that now totals $150 million, reflecting continued investor support as it approaches broader commercialization. The company is based in Hayward, Calif., and emphasizes partnering with pharmaceutical agents and international investors to establish a global footprint. RefleXion develops the RefleXion X1, a biology-guided radiotherapy (BgRT) system designed to treat multiple visible tumors, including those that move due to breathing or digestion, within the same session. The BgRT approach incorporates PET imaging data so tumors continuously signal their location and the system synchronizes those data with a linear accelerator to deliver radiotherapy with subsecond latency. The company recently received FDA clearance for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). RefleXion notes that the BgRT capability requires a separate 510(k) clearance and is not yet available for sale. The company has secured its first system order at a leading cancer center and is focused on scaling market and clinical adoption of the X1 platform. To support commercialization and validation of BgRT in practice, RefleXion closed a $100 million equity financing led by PSP Investments.